ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer.

Huaiyuan Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.